Skip to main content

Table 1 Demographic and clinical characteristics of fatigued vs.nonfatigued subjects

From: Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment

Characteristic

Nonfatigued

Fatigued

P -value

Male (n= 222)

54 (60.00 %)

64(48.48 %)

0.101

Age, y

61.63 ± 9.49

62.50 ± 10.21

0.524

Onset age, y (n= 222)

57.88 ± 9.77

57.89 ± 10.51

0.992

Duration of disease, y (n= 222)

3.75 ± 3.26

4.61 ± 2.99

0.046*

Education, y (n= 222)

10.61 ± 3.12

9.80 ± 3.69

0.09

LEDD (mg/day) (n= 222)

211.19 ± 263.18

280.24 ± 304.04

0.081

H-Y stage (n= 222)

1.73 ± 0.78

2.00 ± 0.76

0.009*

UPDRS total score (n= 222)

39.43 ± 20.26

52.39 ± 20.19

<0.001*

UPDRS part I (n= 222)

2.93 ± 1.93

4.19 ± 2.26

<0.001*

UPDRS part II (n= 222)

9.88 ± 4.80

12.57 ± 5.72

<0.001*

UPDRS part III (n= 222)

25.76 ± 15.37

33.53 ± 14.66

<0.001*

 Postural/gait (sum of UPDRS item 27–30)

3.28 ± 2.80

4.80 ± 3.07

<0.001*

 Bradykinesia (sum of UPDRS item 23–26,31)

12.30 ± 7.98

15.9 ± 7.35

0.001*

 Rigidity (UPDRS item 22)

4.87 ± 4.23

6.45 ± 4.36

0.008*

 Tremor (sum of UPDRS item20 and item21)

3.36 ± 3.26

3.78 ± 3.88

0.391

UPDRS IV (n= 222)

0.86 ± 1.65

1.70 ± 2.57

0.007*

MoCA (n= 222)

22.87 ± 4.59

21.85 ± 4.27

0.066

HAMD (n= 177)

7.26 ± 5.47

9.32 ± 5.17

0.006*

PDSS (n= 177)

119.10 ± 23.65

98.82 ± 25.74

<0.001*

  1. Data are expressed as numbers, with percentages in parentheses, or as mean ± SD. *Significant difference. H-Y stage Hoehn & Yahr staging, LEDD levodopa equivalent daily dosage, UPDRS Unified Parkinson’ Disease Rating Scale, MoCA Montreal Cognitive Assessment, HAMD Hamilton Depression Scale score, PDSS Parkinson’s Disease Sleep Scale